Medical cannabis is not one treatment
Medical cannabis in Spain includes distinct pharmaceutical situations. An authorised medicine has a specific composition and approved indications. A standardised magistral formulation follows a separate regulated process for an individual patient. Both differ from describing an unspecified cannabis product as therapeutic.
The distinction matters to patients because evidence is attached to a preparation used for a defined clinical problem. A positive result in a rare epilepsy syndrome does not establish that every cannabis product treats every kind of seizure, pain or sleep difficulty.
Epidyolex illustrates indication-specific treatment
Epidyolex contains cannabidiol. The European Medicines Agency describes its use alongside clobazam for Lennox-Gastaut or Dravet syndrome from age two, and with other epilepsy treatments for tuberous sclerosis complex in the same age range. Treatment is prescribed and supervised by a clinician experienced in epilepsy.
This is a concrete example of medical cannabis becoming a defined medicine. The active substance, associated treatment and disease are specified. That precision is clinically meaningful: it tells us which patient population and treatment situation the authorisation concerns.
A trial measured fewer seizures, not a universal cure
In a 2017 placebo-controlled trial,120 children and young adults with drug-resistant Dravet syndrome received cannabidiol or placebo in addition to standard treatment. Median monthly convulsive seizures fell from 12.4 to 5.9 with cannabidiol and from 14.9 to 14.1 with placebo. Adverse events included sleepiness and elevated liver enzymes.
The result demonstrates a treatment effect on a defined outcome while also showing why monitoring belongs in the story. It does not mean that every participant became seizure-free. For a patient and family, fewer seizures can be important even when the underlying disease remains.
Spain’s magistral framework adds another clinical route
Royal Decree 903/2025 regulates standardised cannabis preparations used in magistral formulations. Specialist physicians justify prescribing within the framework, hospital pharmacy services prepare and dispense, and clinical teams participate in follow-up. AEMPS’s 2026 National Formulary monograph is published, and the agency maintains the preparation register.
The decree’s rationale identifies areas including multiple-sclerosis spasticity, severe refractory epilepsy, chemotherapy-related nausea and vomiting, and refractory chronic pain. These are not interchangeable claims of equal evidence. The appropriate preparation and applicable conditions remain part of the clinical decision.
Patient experience is part of monitoring
A useful patient account records changes that matter in daily life alongside adverse effects and other treatments. Less pain with disabling sleepiness is different from less pain with maintained function. A symptom change after treatment also needs to be interpreted against the person’s previous course and concurrent care.
The decree includes pharmacotherapeutic follow-up and reporting suspected adverse reactions. That gives patient experience a practical role: it informs ongoing evaluation rather than serving as a universal testimonial. The goal is a defined benefit that remains worthwhile for the person receiving a particular treatment.
Sources & further reading
General information, not individual legal or medical advice.